We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
10 Year Est. Return
AUM
$72.8M
AUM Growth
+$3.96M
Cap. Flow
-$49.2M
Cap. Flow %
-67.59%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 25.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BIOR
1
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$12M 16.52%
1,092,976
PBYI icon
2
Puma Biotechnology
PBYI
$398M
$6.66M 9.15%
1,256,411
-535,703
-30% -$2.88M

Similar funds

Athyrium Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Athyrium Capital Management held 3 positions worth $72.8M, up 5.8% from $68.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management withdrew a net $49.2M in Q1 2024, reducing 1 holding. Its largest reduction was Puma Biotechnology, cutting an estimated $2.88M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 33% a quarter earlier.

  • Athyrium Capital Management's biggest Q1 2024 reduction was Puma Biotechnology, cutting an estimated $2.88M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $72.8M portfolio in Q1 2024.
  • Athyrium Capital Management opened 0 new positions and closed 0 in Q1 2024.
  • Athyrium Capital Management's portfolio value rose 5.8% quarter-over-quarter to $72.8M.

Based on Athyrium Capital Management's 13F filing for Q1 2024, filed 16 May 2024.